The potential risk of metal-centered oxidative catalysis has been overlooked in the research of the copper complexes of the Alzheimer's disease-related β-amyloid (Aβ) peptides. Cu External Met has been determined by kinetic, optical, and electron paramagnetic resonance methods to bind directly to the Cu 2+ center of CuAβ 1-40 and CuAβ 1-20 with K d = 2.8 mM and 11.3 μM, respectively, which reflects less accessibility of the metal center in the full-length CuAβ 1-40 . However, Met does not serve as a reducing agent for the Cu(II) which thus must amplify the observed oxidative catalysis of CuAβ 1-20 through a non-redox mechanism. Conversely, the CuAβ-catalyzed oxidation reaction of dopamine is inhibited by bio-available reducing agents such as ascorbate (competitive K ic = 66 μM) and glutathione (non-competitive, K inc = 53 μM). These data indicate that the oxidation chemistry of metallo-Aβ is not initiated by Met35. The results yield further molecular and mechanistic insights into the roles of metallo-Aβ in this disease.
Introduction
Oxidative stress has been a key topic of research concerning cancer, aging, heart diseases, arthritis, diabetes, and neurodegenerative disorders such as Parkinson's and Alzheimer's diseases (AD) [1] [2] [3] [4] [5] [6] . Mechanisms proposed for the neurodegeneration in the brain of AD patients generally focus on the β-amyloid peptide (Aβ), a proteolytic product of 40-42 amino acids of the ubiquitously distributed amyloid precursor protein (APP), and its complexes of redox-active metal ions [7, 8] . The "Aβ cascade hypothesis" suggests that Aβ aggregates trigger a complex pathological cascade which leads to neurodegeneration in AD [9] , including generation of H 2 O 2 [10] [11] [12] , free-radical induced oxidation [13] [14] [15] such as lipid peroxidation [16] , and the involvement of Met-35 as a reducing agent [17] [18] [19] [20] [21] [22] in the redox chemistry of metallo-Aβ. A central focus of the neuropathology of AD thus has been the effects of redox-active transition metal ions and reactive oxygen species (ROS), such as superoxide, hydroxyl free radical, and H 2 O 2 [7, 8] . Although physiological processes responsible for dealing with ROS can be up-regulated to tackle variations in oxidative stress [23, 24] , long-term effects of such chemical imbalance have been speculated [1] [2] [3] [4] [5] . Some AD treatment strategies have targeted the metal center in metallo-Aβ to prevent peptide aggregation and ROS generation [25] [26] [27] [28] and the role of the metal therein was proposed [29, 30] . However, comparatively little effort has been focused on the mechanism for the metal-centered chemistry, besides the production of H 2 O 2 , which renders direct substrate binding and oxidation by the metal center. If metal-mediated ROS generation is one of the leading causes of oxidative stress, the formation of ROS at the metal site as well as the reactivity of the "metallo-ROS" center [31] in CuAβ may contribute to the oxidative stress suspected to take place in AD [1] [2] [3] [4] [5] . Nevertheless, there are still debates on different views about the role of metalloamyloids even very recently [32] .
Although A-beta accumulation is not likely to be the only factor involved in neuronal cell death, transgenic mouse models with human A-beta have provided significant insights into the neuropathology of AD and behaviors of AD patients, including Aβ aggregation and loss of memory [33] [34] [35] . Rodent Aβ has been shown to exhibit redox activity in vitro that was attributed to ROS generation via Met35 [36] , even though the metal-binding residues were not fully conserved in rodent Aβ (i.e., His13 → Arg). Since Aβ activity and aggregation in AD brains is sequence-specific and metal-dependent [7, 8] , it is a priority to establish the targets of redox activity that can contribute to the physiological and cognitive effects of AD. We have recently established that the Cu II complexes of Aβ and its soluble fragments (Aβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and Aβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] showed considerable activities toward the oxidation of phenol, polyphenol, catechol, and their derivatives to form o-quinones via a type-3 copper-centered mechanism [31, 37, 38] . Such reactivities can explain the mechanism for the formation of dityrosine in Aβ [39] via activation of the phenol side chain and also challenge the redox role of Met35 that is not present in the fragments. Herein we present kinetic and spectroscopic investigations of the oxidation chemistry of CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and the influences of exogenous methionine and reducing agents on its oxidative activity. The results corroborate metal-centered oxidative stress and shed light on the mechanistic roles of Met-35 and reducing agents in the oxidation chemistry of CuAβ.
Materials and methods
The 1-20 fragment of Aβ was synthesized by the use of the Fmoc chemistry at the Peptide Center of the University of South Florida, and the identity of the peptide confirmed with a Bruker MALDI-TOF mass spectrometer. Aβ was obtained from EZBiolab (Westfield, IN). The Cu(II) complexes of Aβ were prepared by addition of 1 equivalent of Cu(II) directly into the peptide solution under experimental conditions, wherein the Aβ 1-40 peptide was dissolved with sonication followed by removal of the undissolved residue with centrifugation. Dopamine, ascorbic acid, and glutathione (GSH) were obtained from Sigma-Aldrich (St. Louis, MO), 3-methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate (MBTH) from Acros (Fairlawn, NJ), and H 2 O 2 , EDTA, L-methionine, and Cu(NO 3 ) 2 from Fisher Scientific (Suwanee, GA). All plastic ware and glassware were demetallized with EDTA and extensively rinsed with 18.0-MΩ deionized water.
The catechol oxidase assay toward dopamine was performed as previously reported [31, 40] . Equal concentrations of dopamine and the o-quinone indicator MBTH were mixed in 100 mM HEPES at pH 7.00 in a final volume of 1.0 mL. The MBTH-adduct of o-quinone was monitored at 505 nm (ɛ = 27,200 M − 1 cm
) and 25°C for 5-10 min with a Varian CARY50 Bio-UV-Vis spectrophotometer equipped with a CARY PCB-150 Water Peltier temperature regulation system, and the rates determined by the change in absorbance over time. The rates were fitted to appropriate rate laws, such as the Michaelis-Mentenlike kinetics [41] , and rate constants determined with non-linear regression. The effects by H 2 O 2 , ascorbate, GSH, and L-Met were determined similarly in the presence of different amounts of the corresponding reagent and the inhibition/dissociation constants determined accordingly. Binding of L-Met to CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] was performed by direct titration of Met into CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] in 100 mM HEPES at pH 7.0 and monitored with the CARY50 spectrophotometer. NMR measurements were performed on a Varian Unity-500 spectrometer.
EPR experiments of the samples under the conditions of the kinetic experiments were performed on a Bruker Elexsys E580 cw/pulsed Xband spectrometer. A typical cw EPR spectrum was obtained with a microwave frequency of 9.4 GHz, field modulation ∼2 G, and time constant of 40-80 ms at ∼ 5-6 K. The g and A tensors were obtained with numerical fittings using the "easyspin" toolbox for Matlab [42] . ESEEM (electron spin echo envelope modulation) spectra were recorded with the usual π/2-τ-π/2-T-π/2 pulse sequence and a π/2 pulse of 20 ns. A typical ESEEM spectrum consists of 1024 points taken at time intervals of 8 ns. The transient was first base-line corrected by subtracting the ordinary T 1 exponential decay function and any remaining constant baseline offset, then zero-appended to 2048 points. A Hamming window function was then applied to the timedomain spin-echo envelope, followed by Fourier transformation to afford the frequency-domain spectrum.
An ESEEM spectrum can reveal those nuclei having superhyperfine coupling with the Cu II center, including coordinated His side chains and water [43] . In the case of coordinated His side chains, the super-hyperfine coupling arises from the electron-nuclear interactions and the nuclear quadrupole interactions (NQI) of the remote non-coordinated nitrogen ( 14 N, I = 1) on the imidazole ring of coordinated His side chains. At X-band, three zero-field nuclear quadrupole resonance lines ν ± and ν o are observed which can be determined from the NQI lines in the ESEEM spectrum (Eqs. (1) and (2)), wherein e 2 qQ is the quadrupole coupling constant and η the asymmetry parameter (η = 0 for a complete axial symmetry and 1 for a pure rhombic symmetry).
2 qQ Þð3FηÞ ð 1Þ
The e 2 qQ and η values can be obtained from the NQI lines in the ESEEM spectra and Eqs. (1) and (2), i.e., (
). In the case of coordinated water, the super-hyperfine coupling can arise from deuterium atoms of deuterated water. The deuterium Zeeman interaction at X-band is much larger than the isotropic component of the electron-nuclear coupling. Thus, the deuterium peak in the ESEEM spectrum is found at the deuterium Zeeman frequency and split slightly by the electron-nuclear coupling.
Results
Dopamine is oxidized by CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] consistent with the metal-centered pre-equilibrium kinetics previously observed [31] . Addition of the amino acid L-Met to the reaction solution significantly increases the oxidative activity (Fig. 1A, B) , which seems to also induce slight cooperativity, e.g., the activity profile with saturating amount of Met gives a Hill's coefficient θ = 2. As opposed to Met, the reducing agents ascorbic acid and GSH act as inhibitors toward dopamine oxidation by CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (Fig. 2) , however, with different inhibition patterns. Herein, GSH was determined to be a noncompetitive inhibitor with an inhibitor constant K inc =53 μM; (Fig. 2A) ; whereas ascorbic acid was revealed to be a competitive inhibitor with an inhibition constant K ic =66 μM (Fig. 2B ).
Upon addition of Met, the electronic spectrum of CuAβ 1-20 exhibits an intense charge-transfer transition at 316 nm ( (Fig. 3, inset) . The X-band EPR spectrum of CuAβ 1-20 can be well fitted to an axial magnetic environment with g // = 2.268, g ⊥ = 2.064, A // = 547, and A ⊥ = 51.1 MHz (Fig. 4A) . These values are consistent with those reported for Cu II complexes of Aβ and fragments [44] , e.g., g // = 2.265-2.269, g ⊥ = 2.059-2.062, and A // = 465-577 MHz. As opposed to the dramatic change in the electronic spectrum, the EPR spectrum changes only slightly to g // = 2.257, g ⊥ = 2.059, A // = 565, and A ⊥ = 35.8 MHz upon Met binding (Fig. 4A) . 
Discussion
Metabolic malfunctions of catecholamine neurotransmitters have been suggested to be related to the neuropathology of AD [45] [46] [47] [48] . Of these neurotransmitters, dopamine is also known to directly link to the neurodegenerative Parkinson's disease [49] and has been proposed to be associated with adult neurogenesis in the subventricular zone [50, 51] . We have recently shown that CuAβ can catalyze oxidation of catecholamine neurotransmitters, including dopamine [31] , to generate neurotoxic quinone products [52] [53] [54] [56, 57] , which may bind and oxidize the substrate (steps iv and v). The presence of a reducing agent such as ascorbic acid can thus facilitate the aerobic pathway to yield the di-Cu I active center (C) ready for O 2 binding and H 2 O 2 production (step vi) [10, 12] . Moreover, the inhibitory effects of ascorbic acid and GSH described herein point to a different mechanism for their action. The binding of ascorbic acid as a competitive inhibitor to the metal in CuAβ that prevents the oxidative catalysis is also consistent with the "antioxidant" role of CuAβ toward ascorbate oxidation previously suggested [58] . A short-cut route analogous to the "peroxide shunt" in heme-containing peroxidase [59] can take place to form the μ-peroxoCu II 2 center upon H 2 O 2 binding (step vii), followed by substrate binding and oxidation (step iv and E). The ternary complex E can also be formed upon H 2 O 2 binding to the intermediate B (step viii), representing a random bi-substrate mechanism.
Met 35 in Aβ has been suggested to serve as a reducing agent [17] [18] [19] [20] [21] [22] responsible for the initiation of the redox cycling of the Cu II center in CuAβ 1-40 which leads to H 2 O 2 production (i.e., step vi in [10, 12] . The oxidation of the thioether moiety of Met to its sulfoxide form in Aβ has been proposed to be involved in aggregation, lipid peroxidation, and redox chemistry in association with the metal center [17] [18] [19] [20] [21] [22] . In the case of the CuAβ 1-20 complex, the activation profile of [Met] (Fig. 1 ) and the optical spectrum (Fig. 3) indicate direct Met binding to the metal in the complex which potentially can reduce the Cu II center as proposed previously for
Met35. In this case, the amount of di-Cu I (C) would increase which in turn would increase the amount of the μ-peroxo-Cu II 2 center upon O 2 binding (D; step iii) and complete the catalytic cycle upon substrate binding (iv and v). Once CuAβ 1-20 is reduced, it cannot follow the peroxide shunt pathway anymore. Our observation that H 2 O 2 can still significantly enhance the activity in the presence of a saturating amount of Met (Fig. 1B) and has an additive effect with Met on the activity suggests that the Cu II center is not significantly reduced by Met.
Moreover, the difference in electrode potentials between Cu II -Aβ and Met is 0.71 V [60] , which gives a dramatic 68.5 kJ difference in Gibbs free energy that is equivalent to a negligibly small equilibrium constant of 9. is most likely to be attributed to other mechanisms which may not be observable under our experimental conditions and time frame, rather than being a reducing agent directly involved in the Cu-centered oxidation chemistry. In the case of the CuAβ 1-40 complex (Figs. 5 and 6 ), the external Met does not significantly enhance the activity as in the case of CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and exhibits a competitive manner with H 2 O 2 as opposed to the additive pattern in the latter case. This observation suggests that the folding of the peptides chain in these two complexes may be different which renders the metal active center less accessible in the case of CuAβ which results in significant decrease in Met affinity and less room for the binding of both the external ligands, Met and H 2 O 2 . This hypothesis is consistent with the observation that Aβ 1-40 has a higher tendency to coagulate more than its short fragments upon metal binding. The presence of the charge transfer band (Fig. 3) is indicative of direct Met binding to the Cu II center. This charge transfer transition is consistent with a thio-to-Cu II charge-transfer transition observed in Cu II -methionine complexes [61] . The K d value of 11.3 μM deviates from the K Ac value obtained from the activity profile discussed above (87 μM), indicating that there are other factors that affect the Met binding to the Cu II center when monitored with activity, such as the cooperativity discussed above (i.e., the formation of the reactive intermediate or synergy due to multiple substrates). The oxidation state of a Cu II center in CuAβ 1-20 upon Met binding can be concluded from the electronic and EPR spectra, wherein the detection of d-d transition at 600-nm (Fig. 3 ) and EPR features (Fig. 4A) indicate that Cu II is not reduced by Met to initiate the oxidative reaction. Met35 was previously suggested to be a reducing agent which initiated the oxidation chemistry of CuAβ 1-40 [17] [18] [19] [20] [21] [22] . The observation herein is consistent with the kinetic results that a Met, internal or external, is not needed for the metal-centered oxidation reaction to take place (Fig. 1) . In the case of CuAβ , the lack of a Met-to-Cu(II) charge-transfer transition at ∼300 nm in the absence of external Met clearly indicate the lack of interaction of the internal Met35 with the metal center. Moreover, the addition of external Met does not create a charge-transfer transition at ∼300 nm, but only a shoulder concomitant with a change in the [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] indicate that there are two pathways for the oxidation of dopamine in the presence of Met and H 2 O 2 , i.e., the pathways i-v and vii-iv-v with a bound Met (the "X" ligand in Fig. 5 ), wherein the enhancement of the activity with Met alone is possibly due to a non-redox mechanism that fine-tunes the reduction potential of the Cu II to favor the oxidative catalysis. The sigmoidal activity profiles for dopamine oxidation in the presence of Met (Fig. 1A) and with both H 2 O 2 and Met (Fig. 1D ) reflect a possible presence of substrate-mediated cooperativity, such as the formation of the dinuclear active center ( Fig. 5; E) . Despite the lack of a Met and any redox-active amino acid, the fragments CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and CuAβ 1-20 exhibit significant metal-centered oxidative activity [31, 37, 38] Fig. 2A) . The inhibitory effect of these reducing agents toward metal-centered catalysis is consistent with the proposed mechanism wherein H 2 O 2 is generated (step vi) [10, 12] . The EPR spectrum of CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] can be attributed to a typical tetragonally distorted Cu II center, i.e., an elongation along the z axis due to the Jahn-Teller effect. The EPR spectral features upon Met binding to CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] confirm the retaining of the d 9 electron
configuration of the Cu II center. The lack of ΔM S = ± 2 transition, i.e., between the M S = −1 and + 1 levels in an antiferromagnetically coupled di-Cu II center [62, 63] potential to favor the oxidation catalysis, yet is not necessarily directly involved in the redox chemistry as a reducing agent. The oxidation of Met35 previously observed may result from the metal-centered oxygenation reaction discussed herein, i.e., Met binds to the metal center (the X in Fig. 5 ) and serves as a substrate via step iv and v without the catechol substrate. If occurred, this reaction would be very slow and beyond the detection limit under the conditions herein.
Concluding remarks
Although reducing agents can potentially inhibit the oxidation of neurotransmitters such as dopamine by CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , yet not to the full extent under physiological conditions [31] , their capability in the production of H 2 O 2 may exacerbate the situation of oxidative stress. Oxidation of dopamine to yield quinone can result in polymerization of tau protein into fibrils [74, 75] and covalent modification of dopamine transporter which directly affects dopamine uptake [76] . Since dopamine plays important roles in behavior and cognition, such as delay-period activity, memory, attention, mood change, pain processing, and motivation, as well as motor activity, long-term oxidation of dopamine may be expected to render physiological and psychological imbalance in the human brain. Moreover, the association of dopamine motor activity and coordination seems to be a common factor that may explain the Parkinsonian-like symptoms in AD patients. Hence, the acceleration of dopamine oxidation via metal-centered mechanism that can be modulated by small molecules such as reducing agents, H 2 O 2 , and/or Met and Met-containing peptides suggests a significant role of CuAβ complexes in the mechanism of oxidative stress in the brain of AD patients. The results herein further support the metallo-ROS-centered redox chemistry of CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [31, 37, 38] and provide additional structural and mechanistic information for the oxidative stress in the brain of AD patients. The role of Met35 has been redefined and the dual mechanistic roles of reducing agents (i.e., inhibition of metal-centered oxidation and H 2 O 2 generation) in the redox cycle of CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] are clearly shown. Although CuAβ and its fragments exhibit similar reactivities, subtle differences are still present which suggests further investigations and comparison are needed for both CuAβ and its fragments to gain a comprehensive understanding of the molecular and mechanistic basis for their roles in AD. The overall picture of AD neuropathology is likely to be composed of the pieces of information uncovered thus far, including generation of ROS, metaldependent aggregation of Aβ, and the largely overlooked metalcentered degradation of biomolecules. Treatment and prevention strategies toward the oxidative stress in AD hence must address all of these pathways, including inhibitions toward H 2 O 2 production and oxidative damage of neurotransmitters and other biomolecules by CuAβ. Further studies targeted toward the elucidation of the metallo-ROS species are being pursued to determine the species responsible for the oxidative activity of CuAβ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
